SCHEMBL27924

SCHEMBL27924

OB(O)c1ccc2ccccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 3/20 0.46
CYP1A2 P05177 2/20 0.46
NOS2 P35228 1/20 0.46
BACE1 P56817 1/20 0.46
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46
MGAM O43451 1/20 0.45
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
AR P10275 2/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
GLA P06280 1/20 0.42
HPGD P15428 1/20 0.42
ACHE P22303 1/20 0.42
CNR2 P34972 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
LMNA P02545 3/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29955954 0.74 ALDH1A1 (0.47) CYP1A2ALDH1A1HPGDCYP3A4KDM4E
Boric Acid SCHEMBL10788055 0.73 AR (0.47) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL29952566 0.72 ESR2 (0.52) CYP1A2ALDH1A1HPGDGAACYP3A4
SCHEMBL31500078 0.72 KDM4E (0.41) CYP1A2BACE1NPC1RAB9AAR
SCHEMBL29957945 0.71 ALDH1A1 (0.47) NPC1RAB9AALDH1A1MAPTHPGD
SCHEMBL3677354 0.71 ALDH1A1 (0.47) NPC1RAB9AALDH1A1MAPTHPGD
SCHEMBL28791 0.71 BACE1 (0.53) CYP1A2BACE1NPC1RAB9AALDH1A1
SCHEMBL6844399 0.70 CCR1 (0.39) RAB9AMAPTLMNACA1CA2
SCHEMBL20067383 0.69 ENPP2 (0.36) ALDH1A1ACHECA1CA2KDM4E
SCHEMBL84064 0.69 NCF1 (0.52) NCF1CYP1A2NOS2BACE1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115679430-B Titanium-aluminum composite part film removing treatment agent and titanium-aluminum composite part surface micropore treatment method 东莞市慧泽凌化工科技有限公司 2026-05-19 CN claimed
CN-119684586-A Polyether base oil and preparation method thereof 万华化学集团股份有限公司 2025-03-25 CN claimed
CN-118908990-A Fluorescence probe based on FRET, preparation method and application thereof in detecting sialic acid 武汉大学 2024-11-08 CN claimed
CN-115010701-B Preparation method of nitrogen-containing heterocyclic derivative 浙江百可半导体材料有限公司 2023-10-13 CN claimed
CN-115010701-A Preparation method of nitrogen-containing heterocyclic derivative 浙江百可半导体材料有限公司 2022-09-06 CN claimed
EP-2176277-B1 NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF UNIV GEORGIA STATE RES FOUND (US) 2016-02-24 EP claimed
US-9096856-B2 Nucleotides and aptamers containing boronic acid groups having biased binding to glycosylated proteins, and uses thereof GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2015-08-04 US claimed
US-20130184160-A1 NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-07-18 US claimed
US-20110144187-A1 APTAMER INHIBITION OF THROMBUS FORMATION GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION 2011-06-16 US claimed
EP-2310054-A2 APTAMER INHIBITION OF THROMBUS FORMATION Georgia State University Research Foundation, Inc. (US) 2011-04-20 EP claimed
EP-2176277-A2 NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF Georgia State University Research Foundation, Inc. (US) 2010-04-21 EP claimed
WO-2010019847-A2 APTAMER INHIBITION OF THROMBUS FORMATION GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2010-02-18 WO claimed
WO-2009012363-A2 NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2009-01-22 WO claimed
CN-115679430-B Titanium-aluminum composite part film removing treatment agent and titanium-aluminum composite part surface micropore treatment method 东莞市慧泽凌化工科技有限公司 2026-05-19 CN disclosed
US-20250311533-A1 LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE HETEROCYCLIC COMPOUND SAMSUNG DISPLAY CO., LTD. (KR) 2025-10-02 US disclosed
EP-4615523-A1 COMPOUNDS AND THEIR USE KING'S COLLEGE LONDON (GB) 2025-09-17 EP disclosed
EP-0968158-A1 METHOD OF PREPARING SUBSTITUTED INDANONES, THE SUBSTITUTED INDANONES AND METALLOCENES PREPARED THEREFROM Basell Polyolefine GmbH (DE) 2000-01-05 EP disclosed
EP-0966442-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1999-12-29 EP disclosed
WO-1999012908-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 1999-03-18 WO disclosed
WO-1998040331-A1 PREPARATION OF PREPARING SUBSTITUTED INDANONES TARGOR GMBH (DE) 1998-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184160-A1 NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF TENT4A, PABPC4, NUDT21 NCF1 2006/4885CYP1A2 4846/4885NOS2 4586/4885
US-20110144187-A1 APTAMER INHIBITION OF THROMBUS FORMATION FGB, F13B, GP6 NCF1 1585/4885CYP1A2 3166/4885NOS2 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.